68 patients referred to a symptomatic breast clinic underwent separate day scintimammography with 740 MBq of Technetium-99m labelled Sestamibi and Oxidronate. 31 patients had subsequent histological confirmation of breast cancer. The primary tumour was identified with both radiopharmaceuticals in 28 patients and missed in 2. A further tumour was missed with Sestamibi but reported as equivocal on Oxidronate imaging. The tumour:background ratios for the 2 radiopharmaceuticals were determined for prone lateral (breasts freely pendant) and supine anterior images. A paired t-test demonstrated no significant difference between the tumour:background count ratios for the 2 radiopharmaceuticals (5% level).
This data supports previously reported data from a smaller series of 7 tumours from the UK (Mackie A. et al 1998, 19: 1101A Nuc. Med. Comm.), which is contrary to the results from another similar sized study of 33 cancers (Nishiyama Y. et al 1999, 213P:1012. Radiol.). The differences between these two studies may be explained by differences in technique and/or patient cohorts.
McCauley E, Mackie A, Bradford IMJ, Cook AIM, Cadigan P. A Comparison of Primary Breast Tumour Contrast with 99mTc.MIBI and 99mTc.HDP Scintimammography. Oral presentation at the British Nuclear Medicine Society AGM, Brighton, April 2000 Nuc Med Commun 2000; 21 (4): 388A.
Dr. Alison Mackie, Durham Unit, Durham. Tel: +44 (0)191-333-2219.
Regional Medical Physics Department, Newcastle General Hospital, Newcastle upon Tyne, NE4 6BE, UK.
Tel: +44 (0)191-233-6161 Fax: +44 (0)191-226-0970 E-mail: webmaster@rmpd.org.uk Web: http://www.rmpd.org.uk
By using this site you agree to our Terms and Conditions of Use. Please read our legal page.
Regional Medical Physics Department, a Clinical Directorate of the Newcastle upon Tyne Hospitals NHS Foundation Trust.
Copyright ©1999-2008 All Rights Reserved. Revised 28 April, 2008.
